Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Ciaran McCrickard)
New ARIA cases dog Biogen's Aduhelm launch in another potential blow to blockbuster hopes — analyst
Perhaps anticipating a walkover with an FDA approval in hand, Biogen has instead faced a wall of pushback over its controversial Alzheimer’s med Aduhelm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
